Expert guidance on the management and challenges of long-COVID syndrome: a systematic review.

INTRODUCTION: Long-COVID is the condition characterised by the permanence of symptoms beyond 4 weeks after initial infection. It affects 1 out of 5 people and is loosely related to the severity of acute infection and pathological mechanisms which are yet to be understood.

AREAS COVERED: This article looks at currently available or under-study therapies for long-COVID syndrome. It particularly gives focus to ongoing trials and review the underlying mechanisms. A comprehensive literature search was performed on PubMed and clincaltrial.gov of clinical trials concerning the management of long-COVID syndrome.

EXPERT OPINION: "Long-COVID" syndrome is a new emergency characterized by several symptoms such as fatigue, dyspnoea, cognitive and attention disorders, sleep disorders, post-traumatic stress disorder, muscle pain, and concentration problems. Despite the many guidelines available to date, there are no established treatments of long-COVID. Pharmacological research is studying known drugs that act on the reduction or modulation of systemic inflammation, or innovative drugs used in similar pathologies. Rehabilitation now seems to be the safest treatment to offer, whereas we will have to wait for the pharmacological research trials in progress as well as plan new trials based on a better understanding of the pathogenic mechanisms.